Price
2,902.2
-3.26%52W Range
Market Cap
₹49,165.02 Cr
Traded: ₹25.31 Cr (0.05%) 0.0x
Free Float: ₹6,106.30 Cr (0.41% of FF traded)
Volume · 60D trend
86.59 K 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
MTF Exposure Trend
60 sessions · funded amount, % of FF, daily delta
LAX.SH
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| Sales | +3.0% | +5.0% | +6.0% | -- | +6.0% | Stable |
| ROE | +33.0% | +48.0% | +43.0% | -- | -- | Stable |
| Return | +5.0% | +9.0% | +24.0% | -9.0% | -- | Stable |
| Profit | +10.0% | +15.0% | +18.0% | -- | +11.0% | Stable |
Quarterly Results
Mar 2023
Dec 2022
Sep 2022
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Jun 2026PDF ↗ | Mar 2026PDF ↗ | Dec 2025PDF ↗ | Sep 2025PDF ↗ | Jun 2025PDF ↗ | Mar 2025PDF ↗ | Dec 2024PDF ↗ | Sep 2024PDF ↗ | Jun 2024PDF ↗ | Mar 2024PDF ↗ | Dec 2023PDF ↗ | Sep 2023PDF ↗ | Jun 2023PDF ↗ | Mar 2023 | Dec 2022 | Sep 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 938 | 995 | 1,041 | 980 | 805 | 974 | 949 | 1,011 | 815 | 930 | 805 | 957 | 762 | 787 | 802 | 917 |
| Expenses | 643 | 644 | 670 | 644 | 554 | 641 | 658 | 689 | 584 | 673 | 587 | 668 | 618 | 618 | 574 | 660 |
| Operating Profit | 296 | 351 | 371 | 336 | 251 | 333 | 292 | 322 | 231 | 257 | 218 | 289 | 144 | 170 | 229 | 257 |
| OPM % | 31.0% | 35.0% | 36.0% | 34.0% | 31.0% | 34.0% | 31.0% | 32.0% | 28.0% | 28.0% | 27.0% | 30.0% | 19.0% | 22.0% | 29.0% | 28.0% |
| Other Income | 44 | 36 | 50 | 36 | 44 | 41 | 35 | 39 | 36 | 32 | -135 | 28 | 54 | 38 | 12 | 22 |
| Interest | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 |
| Depreciation | 16 | 13 | 20 | 17 | 16 | 15 | 19 | 17 | 16 | 18 | 17 | 18 | 16 | 17 | 16 | 16 |
| Profit Before Tax | 322 | 373 | 400 | 354 | 279 | 359 | 308 | 344 | 249 | 271 | 65 | 299 | 181 | 190 | 224 | 262 |
| Tax % | 26.0% | 26.0% | 26.0% | 27.0% | 27.0% | 27.0% | 25.0% | 27.0% | 27.0% | 28.0% | 30.0% | 27.0% | 27.0% | 30.0% | 27.0% | 26.0% |
| Net Profit | 237 | 278 | 296 | 257 | 205 | 263 | 230 | 252 | 182 | 194 | 46 | 218 | 132 | 133 | 165 | 193 |
| Exceptional Items | -- | 0 | 18 | 3 | 0 | 0 | 0 | 5 | 0 | 2 | -163 | 0 | 17 | 10 | -11 | 0 |
| EPS (Rs) | 14.0 | 16.4 | 17.4 | 15.2 | 12.1 | 15.5 | 13.6 | 14.9 | 10.8 | 11.5 | 2.7 | 12.8 | 7.8 | 7.9 | 9.7 | 11.4 |
| Sales Growth (YoY) | 16.5% | 2.2% | 9.7% | -3.1% | -1.2% | 4.7% | 17.9% | 5.6% | 7.0% | 18.2% | 0.4% | 4.4% | -- | -- | -- | -- |
| Sales Growth (QoQ) | -5.7% | -4.4% | 6.2% | 21.7% | -17.4% | 2.6% | -6.1% | 24.1% | -12.4% | 15.5% | -15.9% | 25.6% | -3.2% | -1.9% | -12.5% | -- |
| OP Growth (YoY) | 17.9% | 5.4% | 27.1% | 4.3% | 8.7% | 29.6% | 33.9% | 11.4% | 60.4% | 51.2% | -4.8% | 12.5% | -- | -- | -- | -- |
| OP Growth (QoQ) | -15.7% | -5.4% | 10.4% | 33.9% | -24.6% | 14.0% | -9.3% | 39.4% | -10.1% | 17.9% | -24.6% | 100.7% | -15.3% | -25.8% | -10.9% | -- |
| Profit Growth (YoY) | -- | 6.0% | 23.0% | 3.0% | 12.0% | 36.0% | 29.0% | 15.0% | 52.0% | 53.0% | 3.0% | 12.0% | 3.0% | 369.0% | 13.0% | 2.0% |
| EPS Growth (YoY) | 15.7% | 5.7% | 28.6% | 1.9% | 12.4% | 35.2% | 402.6% | 16.1% | 37.8% | 45.7% | -72.2% | 12.4% | -- | -- | -- | -- |
| EPS Growth (QoQ) | -14.6% | -6.0% | 14.8% | 25.6% | -22.0% | 14.4% | -9.0% | 38.6% | -6.3% | 325.2% | -79.0% | 64.4% | -0.9% | -18.9% | -15.0% | -- |
| OP Margin | 31.6% | 35.3% | 35.6% | 34.3% | 31.2% | 34.2% | 30.8% | 31.9% | 28.3% | 27.6% | 27.1% | 30.2% | 18.9% | 21.6% | 28.6% | 28.0% |
| Net Margin | 25.3% | 27.9% | 28.4% | 26.2% | 25.5% | 27.0% | 24.2% | 24.9% | 22.3% | 20.9% | 5.7% | 22.8% | 17.3% | 16.9% | 20.6% | 21.1% |
| Material Cost % | -- | 34.6% | 34.9% | 36.3% | 35.7% | 36.1% | 37.8% | 38.0% | 36.3% | 39.5% | 39.4% | 37.0% | 38.9% | 43.8% | 35.9% | 39.8% |
| Employee Cost % | -- | 16.6% | 14.6% | 14.1% | 18.9% | 15.7% | 13.1% | 14.9% | 18.6% | 18.6% | 17.6% | 15.2% | 21.7% | 18.9% | 19.1% | 15.5% |
| P/S | 12.43 | 11.77 | 10.92 | 11.75 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/E | 46.03 | 43.42 | 40.63 | 45.60 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/B | 21.69 | 19.84 | 24.30 | 25.52 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Exchange Filings
50As per attachment
As per attachment
As per attachment
IT Refund of Rs 52 crores
Transcript
Outcome of meeting
Glaxosmithkline Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/08/2026 ,inter alia, to consider and approve approve and ....
As per attachment
As per attachment
As per attachment
As per attachment
As per attachment
As per attachment
As per attachment
Annual Report for 2025-26
BRSR Report for 2025-26
As per attachment
As per attachment
Resignation of Dr. Simrat Sohal as Compliance officer of the Company
As per attachment
Annual Compliance Secretarial Report for year ended March 2026
As per attachment
As per attachment
outcome of meeting
As per attachment
As per attachment
Investor Presentation
As per Attachment
As per attachment
Outcome of Meeting
As per attachment
Analyst Meet on 13th May 2026
Publication of special window for share transfer and Saksham Niveshak Campaign
Glaxosmithkline Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/05/2026 ,inter alia, to consider and approve Audited Financial ....
Appointment of Mr. Vinay Subramanian Commercial Head, Oncology
As per attachment
As per attachment
As per attachment
As per attachment
As per attachment
As per attachment
As per attachment
As per attachment
As per attachment
As per attachment
As per attachment
As per attachment
As per attachment
As per attachment
As per attachment
Annual Reports
15Concalls
14Feb 2026
28 Feb 2026Nov 2025
30 Nov 2025Aug 2025
31 Aug 2025May 2025
31 May 2025May 2025
31 May 2025Feb 2025
28 Feb 2025Oct 2024
31 Oct 2024Aug 2024
31 Aug 2024May 2024
31 May 2024Feb 2024
29 Feb 2024Mar 2023
31 Mar 2023Aug 2022
31 Aug 2022Aug 2021
31 Aug 2021Feb 2020
29 Feb 2020Held by ETFs
21 ETFs hold GLAXO · sorted by weight
Held by Mutual Funds
55 schemes hold GLAXO · sorted by weight